On September 20, 2026, ANVISA (Agência Nacional de Vigilância Sanitária) and Receita Federal published updated compliance checklists for personal imports of prescription oncology medicines into Brazil. Patients in São Paulo, Rio de Janeiro, Brasília, and across all Brazilian states can legally import their prescribed cancer treatments when they follow documented regulatory requirements.

At Critical Kare Pharma, we operate a direct-to-patient GDP shipping protocol with Brazilian customs coordination, guaranteeing authentic medicines and complete ANVISA documentation for every shipment.

ANVISA Personal Import Requirements

To legally import oncology medicines into Brazil, patients must comply with the following:

• Valid Prescription (Receita Médica): A prescription from a CRM-registered physician specifying the medicine, dosage, and patient details.
• Personal Use Declaration: Imports are restricted to quantities for individual therapeutic use — typically up to a 90-day supply per shipment.
• Customs Documentation: Commercial invoice, Certificate of Analysis (COA), packing list, and ANVISA regulatory declarations must accompany every package for Receita Federal clearance.
• Cold-Chain Standards: Biological medicines require WHO-GDP certified thermal packaging with validated 2–8°C maintenance and downloadable temperature logs.

Explore our full Brazil resource hub at Brazil cancer medicine page or email support@Critical Kare Pharma.com.